Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 3;14(4):574-578.
doi: 10.3390/idr14040061.

Efficacy and Safety of the Treatment of Chronic Hepatitis C with Sofosbuvir/Ledipasvir in Children Aged 5 to 10 Years with Comorbidities-A Brief Report

Maria Pokorska-Śpiewak  1   2 , Anna Dobrzeniecka  2 , Agnieszka Ogrodnik  3
Affiliations

Efficacy and Safety of the Treatment of Chronic Hepatitis C with Sofosbuvir/Ledipasvir in Children Aged 5 to 10 Years with Comorbidities-A Brief Report

Maria Pokorska-Śpiewak et al. Infect Dis Rep. .

Abstract

The efficacy and safety of 12 weeks of therapy with sofosbuvir/ledipasvir in three patients aged 5-10 years are presented. All three children suffered from comorbidities, including chronic kidney disease in two. All participants achieved a sustained virologic response 12 weeks after the end of treatment. No adverse effects were reported during or after the treatment, and the compliance was good. Decisions on starting treatment in children below 6 years of age should be made individually, taking compliance into consideration. The adjustment of formulation and dosing of medication during treatment is necessary in young children. Further research with larger groups of patients is needed to confirm our findings.

Keywords: children; chronic kidney disease; direct acting antiviral; hepatitis C virus; sofosbuvir/ledipasvir.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Similar articles

See all similar articles

References

    1. Balistreri W.F., Murray K.F., Rosenthal P., Bansal S., Lin C.H., Kersey K. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12–17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017;66:371–378. doi: 10.1002/hep.28995. - DOI - PubMed
    1. Murray K.F., Balistreri W.F., Bansal S., Whitworth S., Evans H.M., Gonzalez-Peralta R.P. Safety and Efficacy of Ledipasvir-Sofosbuvir with or without Ribavirin for Chronic Hepatitis C in Children Ages 6–11. Hepatology. 2018;68:2158–2166. doi: 10.1002/hep.30123. - DOI - PubMed
    1. Indolfi G., Giometto S., Serranti D., Bettiol A., Bigagli E., De Masi S. Systematic review with meta-analysis: The efficacy and safety of direct-acting antivirals in children and adolescents with chronic hepatitis C virus infection. Aliment. Pharm. Ther. 2020;52:1125–1133. doi: 10.1111/apt.16037. - DOI - PubMed
    1. Pokorska-Śpiewak M., Dobrzeniecka A., Aniszewska M., Marczyńska M. Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years-Results of the POLAC Project. J. Clin. Med. 2021;10:4176. doi: 10.3390/jcm10184176. - DOI - PMC - PubMed
    1. Serranti D., Nebbia G., Cananzi M., Nicastro E., Di Dato F., Nuti F., Garazzino S., Silvestro E., Giacomet V., Forlanini F., et al. Efficacy of Sofosbuvir/Ledipasvir in Adolescents with Chronic Hepatitis C Genotypes 1, 3, and 4: A Real-world Study. J. Pediatr. Gastroenterol. Nutr. 2021;72:95–100. doi: 10.1097/MPG.0000000000002900. - DOI - PubMed

LinkOut - more resources